

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT BY
APPLICANT UNDER 37 CFR 1.97(i)**
(Use as many sheets as necessary)

Complete if Known

Application Number	10/735,863
Filing Date	2003-12-15
First Named Inventor	Lee Brettman
Art Unit	1644
Examiner Name	Schwadron, Ronald B.
Docket Number	079259-0237

Sheet	1	of	3
-------	---	----	---

[illegible]

EXAMINER'S INITIALS	CITE NO	Publication Number	Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

[illegible]

Subst. for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT UNDER 37 CFR 1.97(i) <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/735,863
				Filing Date	2003-12-15
				First Named Inventor	Lee Brettman
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
June 24, 2009					
Sheet	2	Of	3	Docket Number	079259-0237
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	AV5	KOLA, Ismail, et al., "Can the pharmaceutical industry reduce attrition rates?", Nature Reviews, Drug Discovery, August 2004, pp 711-715, Vol. 3			
	AW5	MA, Philip, et al., "Value of novelty?", Nature Reviews, Drug Discovery, August 2002, pp 571-572, Vol. 1			
	AX5	FEAGAN, Brian G., et al., "Treatment of Ulcerative Colitis with a Humanized Antibody to the $\alpha_4\beta_7$ Integrin", N. Engl. J. Med., 352:2499-2507 (2005).			
	AY5	FEAGAN, BG, et al., "Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin", Clin Gastroenterol Hepatol., 2008 Dec;6(12):1370-7 (Abstract only)			
EXAMINER			DATE CONSIDERED		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to applicant
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached

Subst. for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT UNDER 37 CFR 1.97(i) <i>(Use as many sheets as necessary)</i> June 24, 2009				Complete if Known	
				Application Number	10/735,863
				Filing Date	2003-12-15
				First Named Inventor	Lee Brettman
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
	3		3	Docket Number	079259-00237


CERTIFICATION STATEMENT

Please See 37 CFR 1.97 and 1.98 to make the appropriate selection(s)

- ☐ Items contained in this Information Disclosure Statement were first cited in any communication from a foreign patent office in a counterpart foreign application;
- ☐ In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☐ This Statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicant understands that the Examiner will make an independent evaluation of the cited publications.
- ☒ The Commissioner is hereby authorized to charge the fee pursuant to 37 CFR 1.17(P) in the amount of \$180.00, or further fees which may be due, to Deposit Account 50-1133.
- ☒ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.


 Kristin A. Connarn, Reg. No.: 57,025
 McDermott Will & Emery LLP
 28 State Street
 Boston, MA 02108
 Tel. (617) 535-4453
 Fax (617) 535-3800
 BST99 1622784-1 079259 0237

Date: June 24, 2009